Behandling af reumatoid artrit med anti-tumornekrosefaktor-a-antistof. Individuel monitorering af biotilgængelighed og immunogenicitet - sekundaerpublikation
Engelsk titel: Treatment of rheumatoid arthritis (RA) with anti-TNF-a antibody (Remicade). Individual monitoring of bioavailability and immunogenicity - secondary publication
Läs online
Författare:
Bendtzen K
;
Geborek P
;
Svenson M
;
Larsson L
;
Kapetanovic MC
;
Saxne T
Email: kben@mail.dk
Språk: Dan
Antal referenser: 10
Dokumenttyp:
Artikel
UI-nummer: 07021820
Sammanfattning
Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 µg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.